news.cision.com

· corpuls is a leading global medical technology provider, focusing on high quality and innovative products for professional users in emergency situations. · The Company sells its products in more than 60 countries with a particular focus on portable defibrillator and monitoring systems as well as devices for mechanical chest compression and the corresponding software solutions. · Based on its extensive experience in the healthcare sector, Nordic Capital will support corpuls’ continued growth trajectory in close partnership with the founding family and the management team, while

Salmon Evolution ASA: Notice of Extraordinary General Meeting

19 April 2023: Reference is made to the stock exchange announcements by Salmon Evolution ASA (“Salmon Evolution” or the “Company”) on 19 April 2023 regarding a successfully placed private placement (the “Private Placement”) of new shares in the Company, and a potential subsequent offering (the “Subsequent Offering”). Salmon Evolution hereby calls for an extraordinary general meeting (“EGM”) in the Company to be held on 11 May 2023 at 11:00 (Oslo time), where the approval of share capital increase pertaining to tranche 2 of the Private Placement and a board authorization to issue new

Avensia Partners With Bluestone PIM

Modern commerce expert Avensia has entered a strategic partnership with Bluestone PIM , a rapidly growing product information management solution with global presence. The new agreement allows Avensia to meet specific customer demands and expand reach to new target audiences.Information management is one of Avensia’s core competence areas. The Avensia team has thorough knowledge and extensive experience in supporting businesses with strategies, processes and technology for efficient information management. Current technology partners include global leaders

Invitation to presentation of Bravida’s report for the first quarter 2023

Bravida’s report for the first quarter 2023 will be published 07:30 CET on 3 May 2023.The report will be presented at 09:30 CET by CEO and Group President Mattias Johansson and CFO Åsa Neving. The presentation will be held in English and can be followed on the web or on the phone. There will be room for questions in the telephone conference. Link to webcasthttps://ir.financialhearings.com/bravida-holding-q1-2023/register Telephone conference dial-in numberSE: +46-8-5051-6386UK: +44-20-319-84884US: +1-412-317-6300PIN: 5403368# The report and presentation will be

Towards harvest 2023 – spring farming in full swing

Wed, Apr 19, 2023 08:54 CET

Somewhat later than usual, Swedish farmers are now starting the intensive work with spring farming. Large autumn sowing, a mild winter rest and stable global demand are factors that will affect the harvest year 2023. The conditions are good for a normal-sized Swedish harvest, but as always, the harvest outcome is ultimately determined by the weather.After large autumn sowing, a mild winter rest and a spring with more precipitation than usual, spring farming is now beginning in large parts of southern and central Sweden. The autumn crops, with the exception of the autumn-sown rapeseed, have

Read original

Major Shareholding Disclosure – Private Placement

19 April 2023: Reference is made to the stock exchange notice by Salmon Evolution ASA (the “Company”) on 19 April 2023 regarding the successfully placed private placement of a total of 68,181,818 new shares in the Company with a subscription price of NOK 7.7 per share divided into two tranches, whereby tranche 1 consisting of 51,863,220 shares and tranche 2 consisting of 16,318,598 shares (the “Private Placement”). Farvatn Private Equity AS was allocated 1,290,000 shares in the Private Placement. Upon completion of the Private Placement through the issue of all shares in the Private

BioStock: Chordate presents study results for the American Headache Society

Wed, Apr 19, 2023 08:53 CET

The final results from Chordate Medical’s PM007 study show that K.O.S. has a significant effect for the preventive treatment of chronic migraine. The results will be presented at the American Headache Society Scientific Meeting in mid-June and are also available on the organisation’s website.Read the full article at biostock.se: https://www.biostock.se/en/2023/04/chordate-presents-study-results-for-the-american-headache-society/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Clinical Laserthermia Systems Announces Agreement with AVANT Concierge Urology to Treat Prostate Cancer Patients with TRANBERG Thermal Therapy System

Wed, Apr 19, 2023 08:50 CET

Lund, Sweden – April 19, 2023 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas has signed a Mobile Service Provider (MSP) Agreement with AVANT Concierge Urology of Winterhaven, FL.Under the agreement, AVANT will begin using the CLS TRANBERG Thermal Therapy System to treat patients with early-intermediate stage prostate cancer. According to the agreement, CLS provides its 510(k) cleared TRANBERG Thermal Therapy System, with consumable accessories,

Fazer includes food loss as a metric in its 2023 Short-Term Incentive plan

Wed, Apr 19, 2023 08:45 CET

Fazer’s Board of Directors has decided to broaden the ESG (Environmental, Social, and Governance) criteria in the company’s Short-Term Incentive plan (STI), and to include food loss as a metric, in addition to Employee Safety, which has long been an ESG priority for Fazer. The portion of the ESG basket in the 2023 STI plan amounts to 15% of the total, highlighting the importance of ESG to the Group. The remainder of the annual STI performance criteria include Group and Business Area financial performance related goals.Food loss has a major impact on climate, water, land and biodiversity.

Observit AB publishes stock analysis from Carlsquare and summons to an extraordinary General meeting ahead of listing.

Wed, Apr 19, 2023 08:45 CET

Carlsquare has published a stock analysis regarding Observit AB, which was distributed to SpectrumOne’s shareholders during July 2022. SpectrumOne still holds 16,7 % of the shares in Observit AB. In the analysis, Carlsquare points to a share price between SEK 0.28 – 0.48/share in a base and a bull scenario respectively. Furthermore, Observit AB has summoned to an extraordinary General meeting to elect Thomas Jönsson and Johan Lembre as new board members. Johan Lembre is CTO at the lighting company Fagerhult Group and before that Johan was CEO at the Swedish headphone company Earin. He

Katalysen portfolio company InvitePeople reports strong progress in German market

Katalysen Ventures is excited to announce that portfolio company and event-tech leader InvitePeople has entered the DACH region, with the aim to replicate its Nordic-market success in the ten times larger German-speaking European market.InvitePeople, the virtual platform for true digital and hybrid events and meetings, has formally entered the large German-speaking European market by acquiring a Berlin-based company with about 10 employees. This Berlin-based company has now been transformed from its previous event-related business to become the foundation for InvitePeople Germany, selling

NOTE’s Interim Report January–March 2023

Financial performance January–March• Sales increased by 28% to SEK 1,051 (821) million. Adjusted for acquisitions and currency effects, organic growth was 14%.• Operating profit increased by 48% to SEK 112 (76) million.• The operating margin widened by 1.4 percentage points to 10.7% (9.3%).• Profit after financial items was up by 50% to SEK 104 (69) million.• Profit after tax rose by 51% to SEK 85 (56) million, corresponding to SEK 2.92 (1.95) per share.• Cash flow after investments amounted to SEK 49 (9) million, or SEK 1.69 (0.31) per share. Adjusted for acquisition-related

Invitation to presentation of BioArctic’s first quarter report for January - March 2023 on April 27 at 9.30 a.m. CET

Stockholm, Sweden, April 19, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s first quarter report for January – March 2023 on Thursday, April 27, 2023, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on April 27, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the first quarter report for January – March 2023, followed by a Q&A-session. If you wish to participate via webcast, please use the link below.

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail. April 19 2023 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Wednesday May 24, 2023 at 17.00 (CET) at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 16.30 (CET).NoticeShareholders wishing to

Scania and Northvolt unveil green battery capable of powering trucks for 1.5 million kilometers

Wed, Apr 19, 2023 08:20 CET

Today, Scania and Northvolt unveiled a jointly developed battery cell for heavy electric vehicles. In validation tests, the lithium-ion cell has demonstrated an outstanding lifetime resulting in the capacity to power trucks for 1.5 million kilometers – equivalent to the truck's whole lifetime. Produced with fossil-free electricity in northern Sweden, the cell’s carbon footprint is approximately one-third that of a comparative industry reference.In 2017, sustainability frontrunners Scania and Northvolt joined forces to develop and commercialize a world-leading battery cell for heavy

CGit AB changes name to Aixia AB

Mölndal 2023-04-19 CGit AB changes name to Aixia AB Aixia AB, formerly known as CGit AB, announces today that the company has changed its name. The new name takes effect immediately. "The name change reflects our strategic focus on developing and delivering innovative solutions that contribute to our continued growth and success." says CEO Mattias Bergkvist. "It is a statement about the company's great potential in tomorrow's IT infrastructure and AI, but also an identity that stands out in the

NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL)

Wed, Apr 19, 2023 08:12 CET

The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Extraordinary General Meeting (“EGM”) to be held on Friday 5 May 2023 at 10.00 a.m. at Good Morning Hotel, Västertorpsvägen 131, in Hägersten. The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to Chapter 7, Section 4 a of the Swedish Companies Act and the Company’s Articles of Associations. Therefore, shareholders may choose to exercise their voting rights at the EGM by attending by

ABGSC to publish Q1 2023 Interim Report on 26 April

Wed, Apr 19, 2023 08:07 CET

ABG Sundal Collier (“ABGSC”) will publish its Q1 2023 figures on 26 April 2023 at 08:00 CEST. The report will be available on our corporate website www.abgsc.com. Webcast presentation CEO Jonas Ström will present the Q1 result through a webcast at 09:00 CEST, followed by a Q&A session. The webcast presentation can be accessed through a web link or call-in details presented on our corporate website www.abgsc.com. For further information: Geir B. Olsen, CFO, +47 22 01 60 35 For media contacts: Anna Tropp, Head of Communications, +46 722 30 94 17

Diaverum welcomes M42 as its new shareholder

Diaverum is announcing today that M42 has entered into a definitive agreement to acquire 100% of the company from Bridgepoint.Diaverum, acquired by Bridgepoint in 2007, is a leading global renal care company that provides essential, life-sustaining dialysis treatments to patients in around 440 clinics across 23 countries worldwide. The company’s main focus is haemodialysis, in conjunction with a portfolio of treatments ranging from preventive care, peritoneal dialysis and home care to the coordination of patients’ comorbidities and their preparation for kidney transplantation. Diaverum

Esmaeilzadeh Holding publishes net asset value as of 31 March 2023

As of 31 March 2023, the net asset value for Esmaeilzadeh Holding AB (publ) was SEK 7.59 billion (SEK 7.62 billion as of 28 February 2023), corresponding to a net asset value per share of SEK 9,848 (SEK 9,886 as of 28 February 2023). For further information, please contact: Saeid Esmaeilzadeh, CEO and founder +46 707 18 70 61, saeid@ehab.group Nils Fredrik Lagerstrand, General Counsel & Deputy CEO +46 720 90 26 99, nilsfredrik@ehab.group The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 19 April 2023.

Lytix Biopharma appoints new Chairman of the Board

Oslo, Norway, April 18, 2023 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces the election of a new Chairman of the Board at today’s General Assembly. The new Chairman is Dr Marie Roskrow, a senior executive with international experience in both lifesciences and investment banking.Dr Roskrow holds a medical degree and a PhD in Immunology and serves currently as the Chairman of a number of international biotechnology companies. “I’m very excited that Marie Roskrow is joining Lytix as the new Chairman of our board. Marie has

Notice to attend the Annual General Meeting of Bricknode Holding AB (publ)